DAPA CKD Trial: Dapaglifloxin to improve diabetic nephropathy

 Diabetic nephropathy is a serious complication of type 1 diabetes and type 2 diabetes. It's also called diabetic kidney disease. In the United States, about 1 in 3 people living with diabetes have diabetic nephropathy. Trial published in American College of Cardiology aimed to assess the safety and efficacy of dapagliflozin in reducing renal events among patients with chronic kidney disease (CKD) with or without diabetes mellitus (DM).

The DAPA-CKD trial showed that dapagliflozin results in salutary effects on renal function and mortality among patients with chronic kidney disease, irrespective of Diabetes Mellitus status. There were also beneficial effects noted on non-Cardiovascular and all-cause mortality. Results were sustained among patients with or without known cardiovascular disease or Heart Failure at baseline.

In a total of 2152 participants randomized in a 1:1 fashion to either dapagliflozin 10 mg daily or 2152 in placebo . The results of this trial indicate that dapagliflozin results in beneficial effects on renal function among patients with Chronic Kidney Disease, with or without Diabetes Mellitus, who already on maximal tolerated doses of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.